Biocept Joins the Russell Microcap® Index
June 28 2021 - 8:05AM
Business Wire
Biocept (Nasdaq: BIOC), a leading provider of molecular
diagnostic assays, products and services, announces that it will be
added to the Russell Microcap Index after the U.S. market opens
today, June 28, 2021.
“We are pleased that Biocept will now be included in the Russell
Microcap Index, which is a broadly used performance benchmark for
smaller growth stocks in the U.S.,” said Michael Nall, President
and CEO of Biocept. “This is an exceptionally exciting time with
the full commercial launch underway of our novel, proprietary
CNSide™ assay that provides physicians with a significantly
improved tool to diagnose and manage patients with tumors that have
metastasized to the central nervous system. We believe the addition
to the Russell Microcap Index will further raise awareness of
Biocept within the global investment community.”
Membership in the Russell Microcap Index, which remains in place
for one year, means automatic inclusion in the appropriate growth
and value style indexes. FTSE Russell, a leading global index
provider, determines membership for its Russell indexes primarily
by objective, market-capitalization rankings and style
attributes.
Russell indexes are widely used by investment managers and
institutional investors for index funds and as benchmarks for
active investment strategies. Approximately $10.6 trillion in
assets are benchmarked against Russell’s U.S. indexes. For more
information on the Russell Microcap Index and the Russell indexes
reconstitution, go to the “Russell Reconstitution” section on the
FTSE Russell website.
About Biocept Biocept, Inc. develops and performs
molecular diagnostic assays that provide physicians with clinically
actionable information for treating and monitoring patients
diagnosed with a variety of cancers. In addition to its broad
portfolio of blood-based liquid biopsy assays, Biocept has
developed the CNSide™ cerebrospinal fluid assay that detects cancer
that has metastasized to the central nervous system. Biocept’s
patented Target Selector™ technology captures and quantitatively
analyzes CSF tumor cells for tumor-associated molecular markers,
using technology first developed for use in blood. Biocept also is
leveraging its molecular diagnostic capabilities to offer
nationwide COVID-19 RT-PCR testing to support public health efforts
during this unprecedented pandemic. For more information, visit
www.biocept.com. Follow Biocept on Facebook, LinkedIn and
Twitter.
Forward-Looking Statements Disclaimer This release
contains forward-looking statements that are based upon current
expectations or beliefs, as well as a number of assumptions about
future events. Although we believe that the expectations reflected
in the forward-looking statements and the assumptions upon which
they are based are reasonable, we can give no assurance that such
expectations and assumptions will prove to have been correct.
Forward-looking statements are generally identifiable by the use of
words like "will," "expect" and "believe" or the negative of these
words or other variations on these words or comparable terminology.
To the extent that statements in this release are not strictly
historical, including without limitation statements regarding our
belief that the addition to the Russell Microcap Index will further
raise awareness of Biocept within the global investment community,
as well as Biocept’s ability to provide physicians with clinically
actionable information for treating and monitoring patients
diagnosed with a variety of cancers, such statements are
forward-looking, and are made pursuant to the safe harbor
provisions of the Private Securities Litigation Reform Act of 1995.
The reader is cautioned not to put undue reliance on these
forward-looking statements, as these statements are subject to
numerous risks and uncertainties, including: the market prices for
our common stock have historically been volatile and will likely
continue to be volatile for the foreseeable future; securities or
industry analysts could issue an adverse opinion regarding our
stock or not publish research or reports about our company, in
which case our stock price and trading volume could decline; there
is no guarantee that our common stock will continue to be included
in the Russell Microcap Index; and our products and services may
not perform as expected. These and other risks are described in
greater detail under the "Risk Factors" heading of our Quarterly
Report on Form 10-Q for the quarter ended March 31, 2021, as filed
with the Securities and Exchange Commission (SEC) on May 12, 2021.
The effects of such risks and uncertainties could cause actual
results to differ materially from the forward-looking statements
contained in this release. We do not plan to update any such
forward-looking statements and expressly disclaim any duty to
update the information contained in this press release except as
required by law. Readers are advised to review our filings with the
SEC, which can be accessed over the Internet at the SEC's website
located at www.sec.gov.
View source
version on businesswire.com: https://www.businesswire.com/news/home/20210628005127/en/
Investors Jody Cain LHA Investor Relations
Jcain@lhai.com, 310-691-7100 Media Andrea Sampson Sampson PR
Group asampson@sampsonprgroup.com, 562-304-0301
Biocept (NASDAQ:BIOC)
Historical Stock Chart
From Aug 2024 to Sep 2024
Biocept (NASDAQ:BIOC)
Historical Stock Chart
From Sep 2023 to Sep 2024